Want to see MCRB full AI Analyst Report?
Top Page
Seres Therapeutics
(NASDAQ:MCRB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-69.70% Downside)
Action:Upgraded
Date:10/28/26
The score is driven primarily by weak financial performance (large ongoing losses and significant TTM cash burn with still-elevated leverage) and bearish technicals (price below all key moving averages with negative MACD). A modest offset comes from the facilities streamlining event, while valuation is not meaningfully supportive due to negative earnings and no dividend data.
Positive Factors
Revenue rebound
The sharp TTM revenue rebound indicates renewed commercial traction and expanding demand for Seres’ microbiome therapeutics. If sustained, stronger revenue can improve operating leverage, support investment in the pipeline, and increase the company’s ability to absorb its substantial fixed costs.
Negative Factors
Persistent unprofitability
Seres remains deeply loss-making despite the revenue rebound and strong gross margin. Heavy operating expenses continue to overwhelm gross profit, leaving limited evidence of sustainable earnings power and making future profitability dependent on substantial cost discipline or further revenue scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The sharp TTM revenue rebound indicates renewed commercial traction and expanding demand for Seres’ microbiome therapeutics. If sustained, stronger revenue can improve operating leverage, support investment in the pipeline, and increase the company’s ability to absorb its substantial fixed costs.
Read all positive factors
Seres Therapeutics (MCRB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.89M
Dividend YieldN/A
Average Volume (3M)71.82K
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue GrowthN/A
EPS Growth71.26%
CountryUS
Employees66
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.38
Shares Outstanding9,941,261
10 Day Avg. Volume53,851
30 Day Avg. Volume71,821
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)2.98
Price to Sales (P/S)167.07
P/FCF Ratio152.39
Enterprise Value/Market Cap6.59
Enterprise Value/Revenue62.64
Enterprise Value/Gross Profit212.53
Enterprise Value/Ebitda-2.63
Forecast
1Y Price Target
$17.00Price Target Upside243.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.51
Revenue Forecast (FY)$13.80M
Seres Therapeutics Business Overview & Revenue Model
Company Description
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, ...
Seres Therapeutics Earnings Call Summary
Earnings Call Date:Nov 05, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call highlighted significant clinical progress and financial recovery, supported by external funding and strategic cost reductions. However, the dependency on securing further capital for future studies poses a notable challenge.Positive Updates
SER-155 Clinical Progress
SER-155 Phase Ib study showed a 77% relative risk reduction in bacterial bloodstream infections, decreased antibiotic exposure, and febrile neutropenia. The FDA provided constructive feedback, aligning on key study parameters for the Phase II protocol.
Negative Updates
Dependence on Funding for Phase II Study
The commencement of SER-155 Phase II study is funding dependent, and the company is actively seeking partnerships or other capital sources.
Read all updates
Q3-2025 Updates
Positive
Negative
SER-155 Clinical Progress
SER-155 Phase Ib study showed a 77% relative risk reduction in bacterial bloodstream infections, decreased antibiotic exposure, and febrile neutropenia. The FDA provided constructive feedback, aligning on key study parameters for the Phase II protocol.
Read all positive updates
Company Guidance
During the Q3 2025 call, Seres Therapeutics highlighted significant advancements related to their lead investigational therapy, SER-155. The therapy showed a 77% relative risk reduction in bacterial bloodstream infections in a Phase Ib study and is progressing to a Phase II study. This study, which targets adults undergoing allo-HSCT, has received Breakthrough Therapy designation from the FDA. Seres anticipates obtaining meaningful clinical results from an interim analysis within 12 months of study initiation, contingent upon funding. The company reported a net income of $8.2 million for Q3 2025, compared to a net loss of $51 million in the same quarter of 2024, due in part to a $25 million installment payment from Nestlé. Their cash position as of September 30, 2025, stood at $47.6 million, expected to fund operations through Q2 2026. Additionally, Seres received a $3.6 million non-dilutive grant from CARB-X for developing a liquid formulation of SER-155, with plans to expand its use in other medically vulnerable populations.Seres Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
35
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.88M | 789.00K | 0.00 | 0.00 | 0.00 | 144.93M |
| Gross Profit | 555.00K | -3.34M | -3.53M | -19.34M | 0.00 | 144.93M |
| EBITDA | -44.87M | 9.83M | -120.30M | -181.42M | -170.93M | -56.72M |
| Net Income | -22.46M | 5.70M | -146.57M | -113.72M | -250.16M | -65.58M |
Balance Sheet | ||||||
| Total Assets | 101.59M | 138.19M | 139.81M | 358.60M | 348.78M | 354.86M |
| Cash, Cash Equivalents and Short-Term Investments | 15.59M | 45.77M | 30.79M | 127.97M | 181.34M | 290.71M |
| Total Debt | 56.64M | 82.97M | 91.64M | 198.78M | 162.59M | 49.21M |
| Total Liabilities | 67.05M | 93.97M | 126.03M | 403.46M | 338.00M | 223.35M |
| Stockholders Equity | 34.53M | 44.22M | 13.78M | -44.86M | 10.78M | 131.51M |
Cash Flow | ||||||
| Free Cash Flow | -51.30M | 865.00K | -148.99M | -125.33M | -238.64M | -2.88M |
| Operating Cash Flow | -51.26M | 1.12M | -148.61M | -117.35M | -228.82M | 6.69M |
| Investing Cash Flow | 187.00K | -42.00K | 142.29M | 10.58M | 82.43M | 64.09M |
| Financing Cash Flow | 14.86M | 13.90M | -90.37M | 71.70M | 129.60M | 1.18M |
Seres Therapeutics Technical Analysis
Negative
4.95
Price Trends
3.78
Negative
4.82
Negative
7.32
Negative
Market Momentum
-0.51
Positive
14.76
Positive
8.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MCRB, the sentiment is Negative. The current price of 4.95 is above the 20-day moving average (MA) of 2.53, above the 50-day MA of 3.78, and below the 200-day MA of 7.32, indicating a bearish trend. The MACD of -0.51 indicates Positive momentum. The RSI at 14.76 is Positive, neither overbought nor oversold. The STOCH value of 8.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MCRB.
Seres Therapeutics Risk Analysis
Seres Therapeutics disclosed 67 risk factors in its most recent earnings report. Seres Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Seres Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $114.03M | -10.75 | -70.44% | ― | ― | 10.04% | |
48 Neutral | $229.05M | -1.64 | -314.08% | ― | 40.21% | 13.40% | |
46 Neutral | $347.08M | -0.72 | 187.62% | ― | -8.79% | -195.46% | |
42 Neutral | $17.89M | -0.76 | -60.32% | ― | ― | 71.26% | |
42 Neutral | $72.19M | -3.95 | -50.17% | ― | ― | 70.27% |
* Healthcare Sector Average
MCRB
Seres Therapeutics
1.80
-15.36
-89.51%
ANIX
Anixa Biosciences
3.28
-0.96
-22.64%
SRZN
Surrozen
29.53
15.80
115.08%
CGTX
Cognition Therapeutics
0.76
-0.83
-52.26%
IMMX
Immix Biopharma
8.05
4.15
106.41%
CAMP
CAMP4 Therapeutics Corporation
3.65
-0.26
-6.65%
Seres Therapeutics Corporate Events
Executive/Board Changes
Seres Therapeutics Announces Upcoming CFO Leadership Transition
Neutral
Oct 26, 2026
On October 22, 2026, Seres Therapeutics announced that Executive Vice President and Chief Financial Officer Marella Thorell resigned from her roles, effective November 15, 2026. Following her effective departure date, Thorell is expected to contin...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes
Positive
Aug 4, 2026
On July 31, 2026, Seres Therapeutics, Inc. executed a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC to end one of its Cambridge facility leases early, aimed at lowering ongoing annual facilities expenses an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.